Several other research analysts also recently commented on the stock. Cowen lifted their target price on shares of MedReleaf from C$20.00 to C$36.00 in a report on Monday, January 8th. Eight Capital lifted their target price on shares of MedReleaf from C$13.00 to C$20.00 and gave the stock a buy rating in a report on Wednesday, November 15th.
MedReleaf (TSE LEAF) opened at C$20.40 on Wednesday. The company has a market cap of $2,040.00 and a price-to-earnings ratio of 1,020.00. MedReleaf has a twelve month low of C$6.81 and a twelve month high of C$31.25.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/02/18/medreleaf-leaf-given-new-c30-00-price-target-at-canaccord-genuity.html.
MedReleaf Company Profile
MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with MarketBeat.com's FREE daily email newsletter.